Alaunos Therapeutics Net Income
| TCRT Stock | USD 2.45 0.13 5.04% |
As of the 6th of February, Alaunos Therapeutics shows the risk adjusted performance of 0.0127, and Mean Deviation of 4.51. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Alaunos Therapeutics, as well as the relationship between them.
Alaunos Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 724.3565 | Revenue | Earnings Share (2.22) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -4.2 M | -4.4 M | |
| Net Loss | -34 M | -35.7 M | |
| Net Loss | -5.4 M | -5.6 M | |
| Net Loss | (2.63) | (2.76) |
Alaunos | Net Income | Build AI portfolio with Alaunos Stock |
The evolution of Net Income for Alaunos Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Alaunos Therapeutics compares to historical norms and industry peers.
Latest Alaunos Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Alaunos Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Alaunos Therapeutics financial statement analysis. It represents the amount of money remaining after all of Alaunos Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Alaunos Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alaunos Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (4.68 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Alaunos Net Income Regression Statistics
| Arithmetic Mean | (59,016,017) | |
| Coefficient Of Variation | (79.14) | |
| Mean Deviation | 36,185,633 | |
| Median | (54,323,000) | |
| Standard Deviation | 46,703,795 | |
| Sample Variance | 2181.2T | |
| Range | 165.2M | |
| R-Value | 0.33 | |
| Mean Square Error | 2071.2T | |
| R-Squared | 0.11 | |
| Significance | 0.19 | |
| Slope | 3,064,628 | |
| Total Sum of Squares | 34899.9T |
Alaunos Net Income History
Other Fundumenentals of Alaunos Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Alaunos Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Alaunos Therapeutics is extremely important. It helps to project a fair market value of Alaunos Stock properly, considering its historical fundamentals such as Net Income. Since Alaunos Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alaunos Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alaunos Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Alaunos introduce new products? Factors like these will boost the valuation of Alaunos Therapeutics. If investors know Alaunos will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Alaunos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.22) | Revenue Per Share | Quarterly Revenue Growth 1 | Return On Assets | Return On Equity |
Understanding Alaunos Therapeutics requires distinguishing between market price and book value, where the latter reflects Alaunos's accounting equity. The concept of intrinsic value - what Alaunos Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Alaunos Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Alaunos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alaunos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Alaunos Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Alaunos Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Alaunos Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Alaunos Therapeutics.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in Alaunos Therapeutics on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding Alaunos Therapeutics or generate 0.0% return on investment in Alaunos Therapeutics over 90 days. Alaunos Therapeutics is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, OSR Holdings, Lipocine, and SeaStar Medical. Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-c... More
Alaunos Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Alaunos Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Alaunos Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.81 | |||
| Information Ratio | (0) | |||
| Maximum Drawdown | 24.31 | |||
| Value At Risk | (10.55) | |||
| Potential Upside | 9.61 |
Alaunos Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alaunos Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Alaunos Therapeutics' standard deviation. In reality, there are many statistical measures that can use Alaunos Therapeutics historical prices to predict the future Alaunos Therapeutics' volatility.| Risk Adjusted Performance | 0.0127 | |||
| Jensen Alpha | 0.026 | |||
| Total Risk Alpha | (0.25) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | (0.14) |
Alaunos Therapeutics February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0127 | |||
| Market Risk Adjusted Performance | (0.13) | |||
| Mean Deviation | 4.51 | |||
| Semi Deviation | 5.55 | |||
| Downside Deviation | 5.81 | |||
| Coefficient Of Variation | 18931.5 | |||
| Standard Deviation | 5.81 | |||
| Variance | 33.78 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | 0.026 | |||
| Total Risk Alpha | (0.25) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | (0.14) | |||
| Maximum Drawdown | 24.31 | |||
| Value At Risk | (10.55) | |||
| Potential Upside | 9.61 | |||
| Downside Variance | 33.76 | |||
| Semi Variance | 30.84 | |||
| Expected Short fall | (5.00) | |||
| Skewness | 0.0455 | |||
| Kurtosis | (0.37) |
Alaunos Therapeutics Backtested Returns
Currently, Alaunos Therapeutics is dangerous. Alaunos Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0207, which signifies that the company had a 0.0207 % return per unit of standard deviation over the last 3 months. We have found twenty-nine technical indicators for Alaunos Therapeutics, which you can use to evaluate the volatility of the firm. Please confirm Alaunos Therapeutics' risk adjusted performance of 0.0127, and Mean Deviation of 4.51 to double-check if the risk estimate we provide is consistent with the expected return of 0.12%. Alaunos Therapeutics has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.15, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Alaunos Therapeutics are expected to decrease at a much lower rate. During the bear market, Alaunos Therapeutics is likely to outperform the market. Alaunos Therapeutics right now shows a risk of 6.01%. Please confirm Alaunos Therapeutics downside variance, and the relationship between the total risk alpha and daily balance of power , to decide if Alaunos Therapeutics will be following its price patterns.
Auto-correlation | -0.6 |
Good reverse predictability
Alaunos Therapeutics has good reverse predictability. Overlapping area represents the amount of predictability between Alaunos Therapeutics time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Alaunos Therapeutics price movement. The serial correlation of -0.6 indicates that roughly 60.0% of current Alaunos Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.6 | |
| Spearman Rank Test | -0.74 | |
| Residual Average | 0.0 | |
| Price Variance | 0.09 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Alaunos Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Alaunos Therapeutics reported net income of (4.68 Million). This is 101.37% lower than that of the Biotechnology sector and 106.68% lower than that of the Health Care industry. The net income for all United States stocks is 100.82% higher than that of the company.
Alaunos Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alaunos Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alaunos Therapeutics could also be used in its relative valuation, which is a method of valuing Alaunos Therapeutics by comparing valuation metrics of similar companies.Alaunos Therapeutics is currently under evaluation in net income category among its peers.
Alaunos Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Alaunos Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Alaunos Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Alaunos Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Alaunos Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Alaunos Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alaunos Therapeutics' value.| Shares | Barclays Plc | 2025-06-30 | 100.0 | Royal Bank Of Canada | 2025-03-31 | 100.0 | Federation Des Caisses Desjardins Du Quebec | 2025-06-30 | 86.0 | Bank Of America Corp | 2025-06-30 | 85.0 | Bank Of Oklahoma National Association | 2025-06-30 | 66.0 | Asset Dedication, Llc | 2025-06-30 | 46.0 | Key Financial, Inc. | 2025-06-30 | 24.0 | Newbridge Financial Services Group, Inc. | 2025-06-30 | 24.0 | Signaturefd, Llc | 2025-06-30 | 23.0 | Blackrock Inc | 21.4 K | Vanguard Group Inc | 2025-06-30 | 21 K |
Alaunos Fundamentals
| Return On Equity | -1.46 | ||||
| Return On Asset | -0.7 | ||||
| Operating Margin | (678.83) % | ||||
| Current Valuation | (594.02 K) | ||||
| Shares Outstanding | 2.23 M | ||||
| Shares Owned By Insiders | 4.37 % | ||||
| Shares Owned By Institutions | 4.82 % | ||||
| Number Of Shares Shorted | 52.25 K | ||||
| Price To Book | 1.95 X | ||||
| Price To Sales | 870.41 X | ||||
| Revenue | 10 K | ||||
| Gross Profit | (910 K) | ||||
| EBITDA | (4.68 M) | ||||
| Net Income | (4.68 M) | ||||
| Cash And Equivalents | 60.01 M | ||||
| Cash Per Share | 0.28 X | ||||
| Total Debt | 692 K | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 2.29 X | ||||
| Book Value Per Share | 1.27 X | ||||
| Cash Flow From Operations | (4.97 M) | ||||
| Short Ratio | 1.03 X | ||||
| Earnings Per Share | (2.22) X | ||||
| Target Price | 1.75 | ||||
| Beta | -1.25 | ||||
| Market Capitalization | 5.22 M | ||||
| Total Asset | 2.75 M | ||||
| Retained Earnings | (920.45 M) | ||||
| Working Capital | 2.06 M | ||||
| Net Asset | 2.75 M |
About Alaunos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alaunos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alaunos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alaunos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Alaunos Stock Analysis
When running Alaunos Therapeutics' price analysis, check to measure Alaunos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alaunos Therapeutics is operating at the current time. Most of Alaunos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alaunos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alaunos Therapeutics' price. Additionally, you may evaluate how the addition of Alaunos Therapeutics to your portfolios can decrease your overall portfolio volatility.